Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study

Condition(s) studied

Investigational drug(s) / intervention(s)

Pegcetacoplan: Solution for infusion for subcutaneous use according to drug use in the real world.

Study summary

The purpose of this study is to evaluate the effectiveness and safety of Pegcetacoplan in patients with C3G and primary IC-MPGN in the real-world setting. This study will also assess biomarkers not routinely measured in clinical practice. Results will support the long-term evaluation of the benefit-risk profile of pegcetacoplan in a broad patient population, informing clinical decision-making.

Eligibility

Primary outcome measure(s)

• Achieving urine protein-to-creatinine ratio (UPCR) of <1 g/g — at 6 months after starting pegcetacoplan treatment
  To describe the real-world clinical effectiveness of pegcetacoplan in participants with C3G or primary IC-MPGN

Trial sites (101)

+ 61 more sites — see the full list on the official registry below.

More Swedish Orphan Biovitrum trials in Australia